相关实验视频

Updated: Jul 2, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

牛皮关节炎的机会窗口:越早越好?

Selinde V J Snoeck Henkemans¹, Pascal H P de Jong², Jolanda J Luime²

¹Rheumatology, Erasmus MC, Rotterdam, The Netherlands s.snoeckhenkemans@erasmusmc.nl.

|February 27, 2024

概括

牛皮关节炎 (PsA) 患者的诊断延迟较短与更好的临床结果有关,突出了早期干预的关键机会窗口. 医生导致的延迟和特定的患者因素,如女性性别或肠炎,导致诊断时间更长.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
临床医学临床医学

背景情况:

牛皮关节炎 (PsA) 诊断和及时治疗对于控制疾病进展至关重要.
了解诊断延迟是识别早期干预机会的关键.

研究的目的:

为了确定是否有一个诊断"机会窗口"存在于牛皮关节炎患者.
为了确定与长时间的诊断延迟相关的患者特征.

主要方法:

分析了708名新诊断的,疾病修饰性抗风湿性前不用药物治疗的PsA患者的队列,随访时间至少3年.
诊断延迟被分为短期 (<12周),中期 (12周至1年) 或长期 (>1年).
临床结果 (最小疾病活性,DAPSA缓解) 和患者报告的结果在延迟组之间进行了比较.

主要成果:

19%的患者出现了短暂的延迟,33%的中等延迟和47%的长期延迟.
延迟时间较短的患者更有可能达到最低疾病活动 (MDA) 和病症活动指数 (DAPSA) 缓解.
女性患者,以及患有肠炎,慢性背痛或正常C-反应蛋白 (CRP) 水平的患者经历了更长的延迟.

结论:

在PsA患者中,早期转诊和在一年内诊断与改善的临床结果相关,这表明"机会之窗".
减少医生的延迟,特别是对于女性患者或患有肠炎,慢性背痛或正常CRP的患者,可以优化患者的治疗结果.

关键词:

关节炎,牛皮,牛皮.结果评估,医疗保健患者报告的结果措施

更多相关视频

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

相关概念视频

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...